View in EDS

High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors.

Saved in:
Bibliographic Details
Title: High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors.
Authors: Gülave B; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands., Hew MN; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands. Electronic address: mn.hew@cbg-meb.nl., de Groot JS; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands., Rodwell L; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands; Biostatistics Section, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Teerenstra S; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands; Biostatistics Section, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Fabriek BO; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands.
Source: ESMO open [ESMO Open] 2021 Jun; Vol. 6 (3), pp. 100107. Date of Electronic Publication: 2021 Apr 20.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33887689
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gülave+B%22">Gülave B</searchLink>; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hew+MN%22">Hew MN</searchLink>; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands. Electronic address: mn.hew@cbg-meb.nl.<br /><searchLink fieldCode="AU" term="%22de+Groot+JS%22">de Groot JS</searchLink>; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Rodwell+L%22">Rodwell L</searchLink>; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands; Biostatistics Section, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Teerenstra+S%22">Teerenstra S</searchLink>; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands; Biostatistics Section, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Fabriek+BO%22">Fabriek BO</searchLink>; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101690685%22">ESMO open</searchLink> [ESMO Open] 2021 Jun; Vol. 6 (3), pp. 100107. <i>Date of Electronic Publication: </i>2021 Apr 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101690685 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-7029 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220597029%22">20597029 </searchLink><i>NLM ISO Abbreviation: </i>ESMO Open <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33887689
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.esmoop.2021.100107
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100107
    Titles:
      – TitleFull: High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gülave B
      – PersonEntity:
          Name:
            NameFull: Hew MN
      – PersonEntity:
          Name:
            NameFull: de Groot JS
      – PersonEntity:
          Name:
            NameFull: Rodwell L
      – PersonEntity:
          Name:
            NameFull: Teerenstra S
      – PersonEntity:
          Name:
            NameFull: Fabriek BO
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2021 Jun
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 2059-7029
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: ESMO open
              Type: main
ResultId 1